MCM
SUPN icon

Mazama Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Mazama Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-6,250
Closed -$40K – 274
2013
Q2 		$40K Buy
+6,250
New +$36.8K 0.02% 154

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MOACM
Mutual of America Capital Management New York $8.8B AUM 29.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mazama Capital Management's SUPN Position: Q3 2013 in Review

Mazama Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2013, closing a stake of 6,250 shares — an estimated $40K sold.

Mazama Capital Management first reported a position in SUPN in Q2 2013 and held it in 1 quarter. The position peaked at $40K in Q2 2013. 57 funds tracked by Wall St. Rank hold SUPN as of Q3 2013.

  • Mazama Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Mazama Capital Management sold 6,250 Supernus Pharmaceuticals shares in Q3 2013, an estimated $40K.
  • Mazama Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Mazama Capital Management's Supernus Pharmaceuticals position peaked at $40K in Q2 2013.
  • 57 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2013.

Based on Mazama Capital Management's 13F filing for Q3 2013, filed 8 Nov 2013.